

BARD1 SHARE PURCHASE PLAN COMPLETED OVERSUBSCRIBED

- **SPP successfully completed with oversubscribed applications of \$3.4m accepted**
- **Total capital raised of \$18.4m under both the SPP and recent placement to institutional and sophisticated investors**
- **BARD1 is now well funded with a pro forma cash balance of approximately \$22.0m to advance its diagnostic programs towards key development and commercialisation milestones over the next 2 years**

Melbourne, Australia, 23 August 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that it has successfully completed the Share Purchase Plan (SPP) announced on 23 July 2021, with applications accepted for \$3.4 million, including oversubscriptions. The Company was seeking to raise up to \$2.0 million through the SPP. However, given the strong support for the SPP by eligible shareholders, the BARD1 Board has exercised its discretion to accept \$3.4 million.

The SPP provided eligible shareholders with the opportunity to purchase new ordinary shares on the same terms as the recently completed placement to institutional and sophisticated investors (Placement) at \$1.55 per share. The Placement was completed on Thursday, 29 July 2021 with a total of \$15 million raised and 9,677,420 fully paid ordinary shares (Shares) issued that commenced trading on the ASX on 30 July 2021.

Both the Placement and SPP capital raising initiatives allocated investors with one free quoted option for every two new Shares subscribed. These options will be quoted on the ASX and tradable. The exercise price of each option is set at \$2.32 and will expire at 5.00pm (Melbourne time) on 24 August 2023.

BARD1 is also pleased to confirm that Dr Geoffrey Cumming (Chairman), Mr Robert (Max) Johnston (Non-Executive Director), Mr Philip Powell (Non-Executive Director) and Dr Leeearne Hinch (CEO), took up their maximum entitlement under the SPP as existing shareholders. Due to Listing Rule restrictions, the options that would have been issued to Directors under the SPP will require the approval of BARD1 shareholders at the 2021 AGM.

Full details of the SPP, SPP Options, and Placement options are set out in a Prospectus which was lodged with ASIC and released to the ASX on 30 July 2021.

A total of 2,200,811 fully paid ordinary shares (SPP Shares), 1,100,333 SPP options and 4,838,686 Placement options will be issued on Tuesday, 24 August 2021 (holding statements are expected to be dispatched Wednesday 25 August 2021) and begin trading on the ASX on Wednesday 25 August 2021.

BARD1 Chief Executive Officer, Dr Leeearne Hinch said: "BARD1 appreciates the strong support received by our existing eligible shareholders under the SPP, which combined with Placement puts the Company in a strong cash position with approximately \$22.0 million to fund the advancement of our diagnostic programs for breast, ovarian and prostate cancer towards key development and commercialisation milestones over the next 2 years."

Dr Geoffrey Cumming, BARD1 Chairman added: "BARD1 is now well positioned to build a sustainable diagnostics business with a diversified portfolio of proprietary technologies, commercialised products and cancer diagnostics pipeline with the potential to deliver real benefits to patients, clinicians, payors and shareholders."

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leeearne Hinch
CEO
E leeearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.